"We could very well reach different decisions about these two businesses," Frazier said at the event in San Francisco. "Whatever action, if any, we intend to conclude by the end of this year."
Crossing the blood-brain barrier is notoriously difficult, but overcoming that obstacle can have vast implications for the treatment of Alzheimer's, Huntington's and brain cancer. Now researchers at Roche have developed an antibody-based technique to "shuttle" large molecules into the brain, increasing exposure to the drug.
Roger Perlmutter has made no secret of the fact that he plans to rapidly execute on the pharma giant's closely watched PD-1 cancer program for MK-3475. The new R&D chief at Merck has carved out the resources and the team needed to put the drug on the shortest path possible to the FDA.
Cambridge, MA's Moderna Therapeutics is marching on with another high-dollar deal, getting $125 million up front to lend its messenger RNA platform to rare disease luminary Alexion Pharmaceuticals.
GlaxoSmithKline has shut the door on its hopes in Duchenne muscular dystrophy, handing back rare-disease drug drisapersen to Prosensa, its former partner.
Swap deals are notoriously difficult to pull off, with the inability to make an "apples-to-apples" comparison of assets scuppering most attempts. Merck and Novartis are reportedly still trying to make a swap deal work though, with the latter's vaccine unit trading hands.
The Switzerland-based biotech has raised $22 million from German billionaire Dietmar Hopp and other backers to advance its Alzheimer's vaccine candidate, ACI-35, into clinical trials.
The game attempts to assess whether someone has Alzheimer's by evaluating how well they respond to distractions and interruptions.
In its short history, the New York Genome Center has bulked up quickly to compete with the established genomics powerhouses, advancing from pilot labs at The Rockefeller University to its own 16,000-square-meter site. Now, it is tapping the University of Buffalo for the computing might needed to handle Big Data storage and complex analytics.
California's Atara Biotherapeutics has heaped more cash onto its second funding round, giving the Amgen spinoff $52 million in Series B funds to support its programs in kidney disease and oncology.